Top

Gepubliceerd in:

01-05-2011

EuroQol (EQ-5D) health utility scores for patients with migraine

Gepubliceerd in: Quality of Life Research | Uitgave 4/2011

Abstract

Purpose

Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity.

Methods

We examined data for 330 20–65-year-old adults, in good physical health, who had 1–6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods.

Results

The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654).

Conclusions

Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.

vorige artikel A cross-sectional validation study of EQ-5D among the Malaysian adult population

volgende artikel Do Portuguese and UK health state values differ across valuation methods?

Alleen toegankelijk voor geautoriseerde gebruikers

Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache, 41(7), 646–657.PubMedCrossRef

Linde, M. (2006). Migraine: A review and future directions for treatment. Acta Neurologica Scandinavica, 114(2), 71–83.PubMedCrossRef

Brown, J. S., Neumann, P. J., Papadopoulos, G., Ruoff, G., Diamond, M., & Menzin, J. (2008). Migraine frequency and health utilities: Findings from a multisite survey. Value Health, 11(2), 315–321.PubMedCrossRef

Flanagan, W., McIntosh, C. N., Le Petit, C., & Berthelot, J. M. (2006). Deriving utility scores for co-morbid conditions: A test of the multiplicative model for combining individual condition scores. Population Health Metrics, 4, 13.PubMedCrossRef

Fryback, D. G., Dasbach, E. J., Klein, R., et al. (1993). The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Medical Decision Making, 13(2), 89–102.PubMedCrossRef

Ko, Y., & Coons, S. J. (2006). Self-reported chronic conditions and EQ-5D index scores in the US adult population. Current Medical Research and Opinion, 22(10), 2065–2071.PubMedCrossRef

Kopec, J. A., Schultz, S. E., Goel, V., & Ivan, W. J. (2001). Can the health utilities index measure change? Medical Care, 39(6), 562–574.PubMedCrossRef

Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2009). Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care, 47(1), 53–60.PubMedCrossRef

Mittmann, N., Trakas, K., Risebrough, N., & Liu, B. A. (1999). Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics, 15(4), 369–376.PubMedCrossRef

10.

Mo, F., Choi, B. C., Li, F. C., & Merrick, J. (2004). Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases. Scientific World Journal, 4, 746–757.PubMed

11.

Saarni, S. I., Harkanen, T., Sintonen, H., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.PubMedCrossRef

12.

Sullivan, P. W., & Ghushchyan, V. (2006). Preference-based EQ-5D index scores for chronic conditions in the United States. Medical Decision Making, 26(4), 410–420.PubMedCrossRef

13.

Wells, K. B., & Sherbourne, C. D. (1999). Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Archives of General Psychiatry, 56(10), 897–904.PubMedCrossRef

14.

Ho, T. W., Mannix, L. K., Fan, X., et al. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 70(16), 1304–1312.PubMedCrossRef

15.

(2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1), 9–160.

16.

Lines, C. R., Vandormael, K., & Malbecq, W. (2001). A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain, 93(2), 185–190.PubMedCrossRef

17.

Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.PubMedCrossRef

18.

Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.PubMedCrossRef

19.

Ekstrom, W., Nemeth, G., Samnegard, E., Dalen, N., & Tidermark, J. (2009). Quality of life after a subtrochanteric fracture: A prospective cohort study on 87 elderly patients. Injury, 40(4), 371–376.PubMedCrossRef

20.

Ekstrom, W., Miedel, R., Ponzer, S., Hedstrom, M., Samnegard, E., & Tidermark, J. (2009). Quality of life after a stable trochanteric fracture—a prospective cohort study on 148 patients. Journal of Orthopaedic Trauma, 23(1), 39–44.PubMedCrossRef

21.

Slatkowsky-Christensen, B., Mowinckel, P., Loge, J. H., & Kvien, T. K. (2007). Health-related quality of life in women with symptomatic hand osteoarthritis: A comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis and Rheumatism, 57(8), 1404–1409.PubMedCrossRef

22.

Lipton, R. B., Diamond, S., Reed, M., Diamond, M. L., & Stewart, W. F. (2001). Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache, 41(7), 638–645.PubMedCrossRef

23.

Johnson, J. A., Luo, N., Shaw, J. W., Kind, P., & Coons, S. J. (2005). Valuations of EQ-5D health states: Are the United States and United Kingdom different? Medical Care, 43(3), 221–228.PubMedCrossRef

24.

Brandes, J. L. (2008). The migraine cycle: Patient burden of migraine during and between migraine attacks. Headache, 48(3), 430–441.PubMedCrossRef

25.

Barbanti, P., Fabbrini, G., Aurilia, C., Vanacore, N., & Cruccu, G. (2007). A case-control study on excessive daytime sleepiness in episodic migraine. Cephalalgia, 27(10), 1115–1119.PubMedCrossRef

26.

Stronks, D. L., Tulen, J. H., Bussmann, J. B., Mulder, L. J., & Passchier, J. (2004). Interictal daily functioning in migraine. Cephalalgia, 24(4), 271–279.PubMedCrossRef

27.

Dahlof, C. G., & Dimenas, E. (1995). Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia, 15(1), 31–36.PubMedCrossRef

28.

Dahlof, C., Loder, E., Diamond, M., Rupnow, M., Papadopoulos, G., & Mao, L. (2007). The impact of migraine prevention on daily activities: A longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes, 5, 56.PubMedCrossRef

29.

Diamond, M., Dahlof, C., Papadopoulos, G., Neto, W., & Wu, S. C. (2005). Topiramate improves health-related quality of life when used to prevent migraine. Headache, 45(8), 1023–1030.PubMedCrossRef

30.

Diener, H. C., Agosti, R., Allais, G., et al. (2007). Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 6(12), 1054–1062.PubMedCrossRef

31.

Diener, H. C., Bussone, G., Van Oene, J. C., Lahaye, M., Schwalen, S., & Goadsby, P. J. (2007). Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 27(7), 814–823.PubMedCrossRef

32.

Dodick, D. W., Silberstein, S., Saper, J., et al. (2007). The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache, 47(10), 1398–1408.PubMedCrossRef

33.

Schrader, H., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2001). Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ, 322(7277), 19–22.PubMedCrossRef

34.

Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA, 289(1), 65–69.PubMedCrossRef

35.

Attema, A. E., & Brouwer, W. B. (2010). On the (not so) constant proportional trade-off in TTO. Quality of Life Research, 19(4), 489–497.PubMedCrossRef

36.

Stalmeier, P. F., Lamers, L. M., Busschbach, J. J., & Krabbe, P. F. (2007). On the assessment of preferences for health and duration: Maximal endurable time and better than dead preferences. Medical Care, 45(9), 835–841.PubMedCrossRef

37.

Wright, D. R., Wittenberg, E., Swan, J. S., Miksad, R. A., & Prosser, L. A. (2009). Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics, 27(9), 713–723.PubMedCrossRef

Titel: EuroQol (EQ-5D) health utility scores for patients with migraine
Publicatiedatum: 01-05-2011
Gepubliceerd in: Quality of Life Research / Uitgave 4/2011
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-010-9783-5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2011

Determinants of quality of life in type 2 diabetes population: the inclusion of personality

Quality of life of children with mitral valve prolapse

Applying area-under-the-curve analysis to enhance interpretation of response profiles: an application to sleep quality scores in patients with fibromyalgia

Gender differences among middle-aged Koreans for health-related quality of life related to metabolic syndrome

Validation of the psychometric properties of the health-promoting lifestyle profile in a sample of Taiwanese women

Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension